

Biographical Sketch

Jan K. Buitelaar, MD PhD
Professor of Child and Adolescent
and of General Psychiatry
Radboud University Medical Center
Nijmegen, The Netherlands

Jan K. Buitelaar MD PhD is Professor of Child and Adolescent Psychiatry and of General Psychiatry at Radboud University Medical Center, Principal Investigator at the Donders Institute for Brain, Cognition and Behavior, and Head of Karakter Child and Adolescent Psychiatry University Center in Nijmegen, The Netherlands. He has been editor-in-chief of European Child and Adolescent Psychiatry for 10 years, and is Chair of the Dutch National Knowledge Center for Child and Adolescent Psychiatry.

He is Vice-President of the World Federation of ADHD, treasurer and member of the Steering Committee of Eunethydis, and member of the European ADHD Guidelines group.

Dr. Buitelaar is a clinical and research expert in neuropsychiatric disorders as ADHD, Autism Spectrum Disorder and Conduct Disorder across the lifespan, and directs neurocognitive, imaging, genetic, translational and pharmacologic and non-pharmacologic treatment studies in these areas. The overall goal of these studies is to identify in closely matched animal and human designs new molecular targets and mechanisms that underlie these disorders and develop and test new interventions. **He is / has been Principal Investigator of several large-scale national and international research projects, and** has published over 600 peer-reviewed papers. He has been awarded several honours, such as the research price of the Dutch Society of Psychiatry in 2011, the international travelling speaker fellowship 2011/2012 of the Association for Child and Adolescent Mental Health, and the Merz Guest Professorship at Goethe University in Frankfurt in 2014.

Dr. Buitelaar has been in the past 3 years a consultant to / member of advisory board of / and/or speaker for Janssen Cilag BV, Eli Lilly, Shire, Roche, Lundbeck, Medice, and Servier. He has received research support from Vifor and Roche. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, royalties.